Future is now: an Australasian perspective on disease-modifying trials in Parkinson's and prodromal disease

Simon J. G. Lewis; Carolyn M. Sue; Antony Cooper; Glenda M. Halliday

doi:10.1136/bmjno-2025-001070

Future is now: an Australasian perspective on disease-modifying trials in Parkinson's and prodromal disease

Simon J. G. Lewis^*, Carolyn M. Sue, Antony Cooper, Glenda M. Halliday

^*Corresponding author for this work

Macquarie Medical School

Research output: Contribution to journal › Article › peer-review

15 Downloads (Pure)

Abstract

There is increasing interest in the role of platform trials, where several investigational products targeting disease modification in Parkinson's Disease can be assessed in parallel. Indeed, several initiatives are currently gearing up across North America and Europe to conduct such studies. However, to date, little attention has been paid to ongoing efforts that already exist in Australia and look soon to expand across to New Zealand as part of greater collaboration. This viewpoint will highlight some of these ongoing efforts addressing the challenges and potential solutions for delivering successful studies.

Original language	English
Article number	e001070
Pages (from-to)	1-3
Number of pages	3
Journal	BMJ Neurology Open
Volume	7
Issue number	1
DOIs	https://doi.org/10.1136/bmjno-2025-001070
Publication status	Published - 21 Mar 2025

Bibliographical note

Copyright the Author(s) 2025. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

Keywords

PARKINSON'S DISEASE
RANDOMISED TRIALS

Access to Document

10.1136/bmjno-2025-001070Licence: CC BY-NC

Publisher version (open access)Final published version, 169 KBLicence: CC BY-NC

Cite this

@article{13130b265fda4245858e826257fe594b,

title = "Future is now: an Australasian perspective on disease-modifying trials in Parkinson's and prodromal disease",

abstract = "There is increasing interest in the role of platform trials, where several investigational products targeting disease modification in Parkinson's Disease can be assessed in parallel. Indeed, several initiatives are currently gearing up across North America and Europe to conduct such studies. However, to date, little attention has been paid to ongoing efforts that already exist in Australia and look soon to expand across to New Zealand as part of greater collaboration. This viewpoint will highlight some of these ongoing efforts addressing the challenges and potential solutions for delivering successful studies.",

keywords = "PARKINSON'S DISEASE, RANDOMISED TRIALS",

author = "Lewis, {Simon J. G.} and Sue, {Carolyn M.} and Antony Cooper and Halliday, {Glenda M.}",

note = "Copyright the Author(s) 2025. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.",

year = "2025",

month = mar,

day = "21",

doi = "10.1136/bmjno-2025-001070",

language = "English",

volume = "7",

pages = "1--3",

journal = "BMJ Neurology Open",

issn = "2632-6140",

publisher = "BMJ Publishing Group",

number = "1",

}

TY - JOUR

T1 - Future is now

T2 - an Australasian perspective on disease-modifying trials in Parkinson's and prodromal disease

AU - Lewis, Simon J. G.

AU - Sue, Carolyn M.

AU - Cooper, Antony

AU - Halliday, Glenda M.

N1 - Copyright the Author(s) 2025. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

PY - 2025/3/21

Y1 - 2025/3/21

N2 - There is increasing interest in the role of platform trials, where several investigational products targeting disease modification in Parkinson's Disease can be assessed in parallel. Indeed, several initiatives are currently gearing up across North America and Europe to conduct such studies. However, to date, little attention has been paid to ongoing efforts that already exist in Australia and look soon to expand across to New Zealand as part of greater collaboration. This viewpoint will highlight some of these ongoing efforts addressing the challenges and potential solutions for delivering successful studies.

AB - There is increasing interest in the role of platform trials, where several investigational products targeting disease modification in Parkinson's Disease can be assessed in parallel. Indeed, several initiatives are currently gearing up across North America and Europe to conduct such studies. However, to date, little attention has been paid to ongoing efforts that already exist in Australia and look soon to expand across to New Zealand as part of greater collaboration. This viewpoint will highlight some of these ongoing efforts addressing the challenges and potential solutions for delivering successful studies.

KW - PARKINSON'S DISEASE

KW - RANDOMISED TRIALS

UR - http://www.scopus.com/inward/record.url?scp=105001184068&partnerID=8YFLogxK

U2 - 10.1136/bmjno-2025-001070

DO - 10.1136/bmjno-2025-001070

M3 - Article

C2 - 40129903

AN - SCOPUS:105001184068

SN - 2632-6140

VL - 7

SP - 1

EP - 3

JO - BMJ Neurology Open

JF - BMJ Neurology Open

IS - 1

M1 - e001070

ER -

Future is now: an Australasian perspective on disease-modifying trials in Parkinson's and prodromal disease

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Cite this